References
- Degenhardt L, Gibson A, Mattick R P, Hall W. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev 2008; 27: 1–3
- Brewer C. Harm reduction in unwanted pregnancies and unwanted addictions: an instructive analogy. Adicciones 2008; 20(1)5–14
- Caplehorn J. Methadone maintenance treatment: Britain has been over-committed to psychological theories of drug dependence. BMJ 1995; 310: 463
- Brewer C. Responses to Gibson AE, Degenhardt LJ, Hall WH. (Opioid overdose deaths can occur in patients with naltrexone implants). Med J Aust 2007; 187: 55
- De Jong C A, Roozen H G, van Rossum L G, Krabbe P F, Kerkhof A J. High abstinence rates in heroin addicts by a new comprehensive treatment approach. Am J Addict 2007; 16: 124–130
- Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1‐month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003; 8: 211–217